With more than 1500% stock returns in 2020 and 2021, Enzolytics Inc. (ENZC) continues to amaze the investment community. The company owns licensing rights of the Irreversible Pepsin Fraction peptide molecule, a new treatment of HIV/AIDS.
Currently at a clinical stage, Enzolytics has made an investment in an european entity, which is conducting trials to prove the new treatment. Given the stock returns, many traders seem to believe that the results will be a success:
Merger With BioClonetics
First, among the most positive announcements recently made, there is the business combination between Enzolytics and BioClonetics. In the press release, the company noted that ENZC is now targeting both HIV and Coronavirus.
Besides, it noted that the company’s treatment of HIV has shown 68% efficacy and statistical significance as compared to the control group. In my opinion, some traders might have acquired more shares after knowing this new information:
The CEO of ENZC also disclosed that the company’s anti-HIV treatment is expected to be extremely cheap for the patients. Notice that the company is expected to offer monoclonal antibodies, like those offered to President Trump when he contracted the Coronavirus:
New Funding, New Accounting Firm, And Perhaps A New Patent
It is also extremely beneficial that Enzolytics Inc. expects to receive additional financing of $1.3 million to support the company’s clinical trials.
On the top of it, investors will most likely appreciate that ENZC expects to hire a new PCAOB audit firm to work on the company’s financial statements. I believe that the company is making all the correct moves to get to the next level:
In January, ENZC also reported the filing of a new patent application for Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor. This is very positive.
If the company can obtain the new patent, ENZC could start the development of new treatment. It could mean additional sales and perhaps more financing.
New Lab In The Campus Of Texas A&M University
There is another extremely valuable information. The company also noted a new lab in the campus of Texas A&M University. According to a press release, ENZC expects to develop new capabilities for the production of monoclonal antibodies targeting HIV and Coronavirus. If you don’t know Texas A&M University, notice that it is ranked top in Texas in MONEY magazine’s new best value rankings:
Disclosure: We don’t hold ENZC shares and we were not paid to write this article.
Stay tuned, we will deliver more information about ENZC in the near future.